Market Cap
$1.4B
DRTS
Alpha Tau Medical Ltd.
$14.77 ▲ +1.79%
Prev close $14.51Market cap$1.4B
ConsensusStrong Buy
12-mo target$17.80 (+20.5%)
▲ Bullish
Analyst conviction 8/10
High Impact Filing (7/10) Healthcare & Medical Devices
Snapshot
The big-picture read on DRTS right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (82%)
Insider Activity
$0.00 buy / $1.6M sell
Insider Net $
-$1.6M
Social Sentiment
57° Neutral
SEC Reports
8
Press Releases
7
Price chart 30d +1.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 31, 2026 SEC Jun 3, 2026 Press
Alpha Tau completed enrollment in its IMPACT pilot study of Alpha DaRT for pancreatic cancer, enrolling 48 patients (4x
6-K — Impact 7/10
Aug 25, 2026 ftd
FTD: DRTS — 44,223 shares ($0.7M) failed to deliver
Settlement: 20260825, Price: $14.70, FTD Value: $650,078.1, ALPHA TAU MED LTD ORD SHS (ISR
Aug 21, 2026 Insider
Levy Raphi acquired via exercise 2,871 shares
Chief Financial Officer @ $2.98 ($8.6K)
Aug 21, 2026 Insider
Aug 11, 2026 SEC Levy Raphi sold 2,871 shares
Chief Financial Officer @ $15.00 ($43.1K)
Alpha Tau Medical reported H1 2026 financial results showing a net loss of $68.8M ($0.76/share), widened from $18.8M ($0
6-K — Impact 7/10
Aug 11, 2026 Insider
Aug 10, 2026 SEC Levy Raphi sold 17,730 shares
Chief Financial Officer @ $14.00 ($248.3K)
Alpha Tau reported Q2 2026 EPS of -$0.26, a 84.6% miss versus consensus of -$0.14, with net loss widening to $68.8M for
PRESS-RELEASE — Impact 8/10
Alpha Tau Medical announced a strategic collaboration with Tolmar Inc. for exclusive U.S. commercialization of Alpha DaR
Impact 7/10
Analyst ratings buy % -8.9%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
82% rate it Buy or better · 11 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 3, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Aug 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jul 22, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jul 16, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jun 4, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jun 4, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Jun 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 28, 2026 | Barclays | INITIATE | Overweight | 54% |
| May 20, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 19, 2026 | Piper Sandler | MAINTAIN | Neutral | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 5 | 2 | 0 | 0 | 82% | |
| Aug 1, 2026 | 4 | 5 | 2 | 0 | 0 | 82% | |
| Jul 1, 2026 | 4 | 5 | 2 | 0 | 0 | 82% | |
| Jun 1, 2026 | 4 | 5 | 2 | 0 | 0 | 82% | |
| May 1, 2026 | 4 | 4 | 2 | 0 | 0 | 80% | |
| Apr 1, 2026 | 4 | 4 | 2 | 0 | 0 | 80% | |
| Mar 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% |
Price targets
Where 5 covering analysts think DRTS trades over the next 12 months.
$17.80 +20.5% upside Strong Buy
Current$14.77 Low$8.00 Median$17.00 High$30.00 5 analysts
$8.00$30.00
Analyst rating None as of Oct 3, 2026
Social media sentiment mood -28.6%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
57°
Neutral
BearishNeutralBullish
Recent posts
Merck and Moderna have shown us what the market premium is for platform validation. Is DRTS the next platform primed to move?
▲ 1 · 💬 5· ⚡ 0.5
Curious if anyone has thoughts about DRTS (Alpha Tau Medical).
▲ 1 · 💬 2· ⚡ 0.5
Do some trading platforms have dodgy algorithms?
▲ 1 · 💬 1· ⚡ 0.5
“There may be a miracle working in my husband’s head right now as he sleeps beside me”: Amazing DRTS patient testimony from GBM trial!
▲ 1 · 💬 5· ⚡ 0.5
SLS, ONDS, DRTS and HOVR
▲ 1 · 💬 1· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 6 bullish, 0 bearish, 1 mixed, 1 neutral · avg impact 6.4/10.Plus 7 press releases.
BULLISH6-K7/10
Alpha Tau completed enrollment in its IMPACT pilot study of Alpha DaRT for pancreatic cancer, enroll
Aug 31, 2026
BULLISH6-K7/10
Alpha Tau Medical reported H1 2026 financial results showing a net loss of $68.8M ($0.76/share), wid
Aug 11, 2026
BULLISHPRESS-RELEASE8/10
Alpha Tau reported Q2 2026 EPS of -$0.26, a 84.6% miss versus consensus of -$0.14, with net loss wid
Aug 10, 2026
NEUTRAL6-K4/10
Alpha Tau Medical announced its intention to dual-list its ordinary shares on the Tel Aviv Stock Exc
Aug 10, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 25, 2026
ftd
FTD: DRTS — 44,223 shares ($0.7M) failed to deliver
Settlement: 20260825, Price: $14.70, FTD Value: $650,078.1, ALPHA TAU MED LTD ORD SHS (ISR
Aug 24, 2026
ftd
FTD: DRTS — 58,996 shares ($0.9M) failed to deliver
Settlement: 20260824, Price: $14.92, FTD Value: $880,220.32, ALPHA TAU MED LTD ORD SHS (ISR
Aug 18, 2026
earnings_calendar
DRTS Q2 2026 Earnings Scheduled — 2026-08-18
Aug 10, 2026
earnings
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Jul 21, 2026
other
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
Alpha Tau Reports Positive Data Demonstrating 100% ORR and 18.2-Month Median OS with Alpha DaRT® in Combination with Pembrolizumab for HNSCC
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.15 | $-0.16–$-0.13 | -4.8% | -6.1% | 1↑ 2↓ | $0.0B | 4 |
| Next Q | $-0.15 | $-0.17–$-0.13 | -8.4% | -9.8% | 0↑ 2↓ | $0.0B | 4 |
| Current FY | $-0.96 | $-1.08–$-0.55 | -80.3% | -45.1% | 1↑ 3↓ | $0.0B | 5 |
| Next FY | $-0.53 | $-0.60–$-0.50 | 44.0% | -3.9% | 1↑ 2↓ | $0.0B | 5 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.147 | — |
| 7d ago | $-0.142 | -0.005 |
| 30d ago | $-0.138 | -0.008 |
| 60d ago | $-0.138 | -0.008 |
| 90d ago | $-0.138 | -0.008 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
1 insiders, 17 transactions. Net -$1.6M — $0.00 bought, $1.6M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 21, 2026 | Levy Raphi | Chief Financial Officer | EXERCISE | 2,871 | $2.98 | $8.6K |
| Aug 21, 2026 | Levy Raphi | Chief Financial Officer | SELL | 2,871 | $15.00 | $43.1K |
| Aug 11, 2026 | Levy Raphi | Chief Financial Officer | SELL | 17,730 | $14.00 | $248.3K |
| Aug 11, 2026 | Levy Raphi | Chief Financial Officer | EXERCISE | 17,730 | $2.98 | $52.8K |
| Jul 6, 2026 | Levy Raphi | Chief Financial Officer | EXERCISE | 2,270 | $2.98 | $6.8K |
| Jul 6, 2026 | Levy Raphi | Chief Financial Officer | SELL | 2,270 | $14.00 | $31.8K |
| Jul 2, 2026 | Levy Raphi | Chief Financial Officer | EXERCISE | 17,873 | $2.98 | $53.3K |
| Jul 2, 2026 | Levy Raphi | Chief Financial Officer | SELL | 17,873 | $13.00 | $232.4K |
| Jul 1, 2026 | Levy Raphi | Chief Financial Officer | EXERCISE | 2,127 | $2.98 | $6.3K |
| Jul 1, 2026 | Levy Raphi | Chief Financial Officer | SELL | 2,127 | $13.02 | $27.7K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for DRTS.
Shares short
3,483,059
Settlement Sep 15, 2026
Change vs prior
+12.6%
Semi-monthly cycle
Days to cover
7.3
At avg daily volume
Of shares outstanding
≈3.8%
Estimate — not % of float
All DRTS filing & press-release reports (15)
- 6-K reportAug 31, 2026
- 6-K reportAug 11, 2026
- PRESS-RELEASE reportAug 10, 2026
- 6-K reportAug 10, 2026
- 6-K reportJul 21, 2026
- 6-K reportJul 15, 2026
- 6-K reportJun 24, 2026
- PRESS-RELEASE reportJun 3, 2026
- PRESS-RELEASE reportMay 11, 2026
- PRESS-RELEASE reportMay 8, 2026
- PRESS-RELEASE reportMay 5, 2026
- PRESS-RELEASE reportMay 4, 2026
- PRESS-RELEASE reportApr 27, 2026
- PRESS-RELEASE reportApr 23, 2026
- PRESS-RELEASE reportMar 9, 2026